



ESMO

GOOD SCIENCE
BETTER MEDICINE
BEST PRACTICE

WORLD CONGRESS ON
**Gastrointestinal
Cancer**

Breakthrough
Research.
Better Outcomes.
A Brighter Future.

A
VIRTUAL
EXPERIENCE



1–4 July
2020

worldgicancer.com

| **HMP Global Event** |

In the spirit of progress and advancement, the 2020 ESMO World Congress on GI Cancer will be delivered as a virtual experience. With more than 90 scientific sessions dedicated to improving the lives of patients with GI cancer, this meeting offers important knowledge for everyone involved.

THE CONGRESS CHAIRS

**DEDICATED TO
DELIVERING UNMATCHED
EDUCATION ON THE
LATEST ADVANCEMENTS
IN GI ONCOLOGY.**



CHAIR

Mario Dicato
Luxembourg, Luxembourg



CHAIR

Eric Van Cutsem
Leuven, Belgium



VICE CHAIR

Josep Tabernero
Barcelona, Spain

Register Today
worldgicancer.com
+1.678.242.0906

Part of the  Oncology
Learning Network

oncnet.com

3.500+
Delegates

120+
Countries
Represented

80+
GI Oncology
Experts

450+
Scientific
Abstracts



A Virtual Experience to Continue the Mission



THE MOST IMPORTANT FORUM FOR GI ONCOLOGY EDUCATION WILL BE OFFERED AS A VIRTUAL EXPERIENCE THIS YEAR TO ENSURE CONTINUED ACCESS TO GROUNDBREAKING RESEARCH AND IMPORTANT CLINICAL INSIGHTS.

The Congress will be completely accessible from the comfort of your home via any device—all you need is an internet connection.

Your Virtual Registration includes:

4 days of live access to the very latest clinical highlights—including 50+ oral abstract presentations, featuring important data and practice-changing insight

Access to all sessions traditionally delivered during a face-to-face gathering—plus additional sessions released weekly as an on-demand component of the educational program

12-month on-demand access to all educational sessions recorded during the live program as well as to those added once the live program concludes—watch at your convenience

Engaging exchange through real-time Q&A and discussion with our globally recognized faculty experts

Beyond the educational program, connect with your global community by participating in independent satellite symposia and networking opportunities, and browsing the exhibit hall.

Visit worldgicancer.com/virtualFAQ to learn more





The Scientific Committee

Composed of some of the world's leading experts, the Scientific Committee has worked to develop a robust and unmatched scientific program for a critical and comprehensive update in GI cancer.

Monica M. Bertagnolli
Brigham and Women's Hospital
Boston, United States

Andrés Cervantes
Biomedical Research Institute INCLIVA
University of Valencia
Valencia, Spain

Fortunato Ciardiello
Università degli Studi della Campania Luigi Vanvitelli
Naples, Italy

Mario Dicato
Luxembourg Medical Center
Luxembourg, Luxembourg

Michel P. Ducreux
Gustave Roussy
Paris, France

Sharlene Gill
BC Cancer - University of British Columbia
Vancouver, Canada

Thomas Gruenberger
Social Medical Center South
Vienna, Austria

Karin Haustermans
University Hospital Gasthuisberg
Leuven, Belgium

David H. Ilson
Weill Cornell Medical College Memorial Sloan Kettering Cancer Center
New York, United States

Florian Lordick
Leipzig University Medical Center
Leipzig, Germany

Erika Martinelli
Università degli Studi della Campania Luigi Vanvitelli
Naples, Italy

Deborah Mukherji
American University of Beirut Medical Center
Beirut, Lebanon

Kei Muro
Aichi Cancer Center Hospital
Nagoya, Japan
Pia Österlund

Tampere University Hospital
Tampere, Finland

Radka Obermannova
Masaryk Memorial Cancer Institute
Brno, Czech Republic

Philip A. Philip
Karmanos Cancer Institute
Detroit, United States

Rachel P. Riechelmann
AC Camargo Cancer Center
São Paulo, Brazil

Erika Ruiz-Garcia
Instituto Nacional de Cancerología
Mexico City, Mexico

Thomas T. Seufferlein
Ulm University
Ulm, Germany

Josep Tabernero
Vall d'Hebron University Hospital
Barcelona, Spain

Eric Van Cutsem
University Hospital Gasthuisberg
Leuven, Belgium

Harpreet Wasan
Imperial College Healthcare
London, United Kingdom

Takayuki Yoshino
National Cancer Center Hospital East
Chiba, Japan

Faculty

Ghassan K. Abou-Alfa
Memorial Sloan Kettering Cancer Center
New York, United States

René Adam
Université Paris Sud Hôpital Paul Brousse
Villejuif, France

Thierry André
Hospital Saint Antoine
Paris, France

Teresa Amaral
Eberhard Karls University
Tuebingen, Germany

Irit Ben-Aharon
Rambam Health Care Campus
Haifa, Israel

Jacques J. Bergman
Academic Medical Center
Amsterdam, Netherlands

Jaume Capdevila
Vall d'Hebron Institute of Oncology
Barcelona, Spain

Andrea Cercek
Memorial Sloan Kettering Cancer Center
New York, United States

Christopher H. Crane
Memorial Sloan Kettering Cancer Center
New York, United States

Christophe Deroose
University Hospital Gasthuisberg
Leuven, Belgium

Rodrigo Dienstmann
Vall d'Hebron Institute of Oncology
Barcelona, Spain

Robert Glynne-Jones
National Health Service
Leeds, United Kingdom

Axel Grothey
West Cancer Center
Germantown, United States

Dow-Mu Koh
The Royal Marsden NHS Foundation Trust
Sutton, United Kingdom

Scott Kopetz
MD Anderson Cancer Center
The University of Texas
Houston, United States

Teresa Macarulla
Vall d'Hebron University Hospital
Barcelona, Spain

Vincenzo Mazzaferro
Istituto Nazionale per lo Studio e la Cura dei Tumori
Milan, Italy

Markus Möhler
University Medicine of the Johannes Gutenberg-University Mainz
Mainz, Germany

Magnus Nilsson
Karolinska Institutet
Karolinska University Hospital
Stockholm, Sweden

Eileen M. O'Reilly
Memorial Sloan Kettering Cancer Center
New York, United States

Michael Overman
MD Anderson Cancer Center
The University of Texas
Houston, United States

Marianne Pavel
Friedrich-Alexander University
Erlangen, Germany

Solange Peters
Lausanne University
Lausanne, Switzerland

Raquel Perez-Lopez
Vall d'Hebron University Hospital
Barcelona, Spain

Rodrigo Perez
Angelita & Joaquim Gama Institute
Hospital Beneficência Portuguesa de São Paulo
São Paulo, Brazil

Maria Reig
Barcelona Clinic Liver Cancer Hospital Clinic de Barcelona
Barcelona, Spain

Alberto F. Sobrero
IRCCS Ospedale San Martino IST
Genoa, Italy

Elizabeth C. Smyth
Cambridge University Hospitals
NHS Foundation Trust
Cambridge, United Kingdom

Zsafia Stadler
Memorial Sloan Kettering Cancer Center
New York, United States

Sabine Tejpar
University Hospital Gasthuisberg
Leuven, Belgium

Juan W. Valle
The Christie NHS Foundation Trust
Manchester, United Kingdom

Mark van Berge Henegouwen
Amsterdam UMC
Amsterdam, The Netherlands

Chris Verslype
University Hospital Gasthuisberg
Leuven, Belgium

Arndt Vogel
Medizinische Hochschule Hannover
Hannover, Germany

Anna-Dorothea Wagner
Lausanne University Hospital
Lausanne, Switzerland

Zev Wainberg
Ronald Reagan UCLA Medical Center
Los Angeles, United States

John R. Zalcberg
Monash University
Melbourne, Australia

***Confirmed as of May 12.**
For the most up-to-date faculty list, please visit worldgicancer.com



Wednesday
1 July 2020

13:00
Welcome and Introduction

13:15
Concurrent Symposia

SESSION I
CANCER OF THE PANCREAS AND
BILIARY TRACT

14:15
Presentation of Selected Abstracts on
Biliary Tract and Pancreatic Cancers

16:24
Live Q&A With Key Opinion Leaders

16:44
Break

17:00
Concurrent Symposia

18:00
KEYNOTE: New Agents on the Horizon
in Metastatic Disease (Biliary Duct and
Pancreatic Cancer)

SESSION II
HEPATOCELLULAR CANCER

18:20
Presentation of Selected Abstracts on
Hepatocellular Cancer

19:58
KEYNOTE: How to Integrate New Agents
in HCC

20:18
Live Q&A With Key Opinion Leaders

20:38
Adjourn



Thursday
2 July 2020

13:00
Welcome and Introduction;
Highlights of Day 1

13:15
Concurrent Symposia

SESSION III
ESOPHAGEAL AND GASTRIC CANCER

14:15
Presentation of Selected Abstracts on
Gastric Cancer


15:58
Live Q&A With Key Opinion Leaders

16:18
Break

16:40
KEYNOTE: Checkpoint Inhibition in
Esophageal and Metastatic Gastric
Cancer

17:00
Concurrent Symposium

18:00
KEYNOTE: New Agents on the Horizon in
Esophageal and Gastric Cancer



SESSION IV
GASTROINTESTINAL STROMAL TUMORS
(GIST); NEUROENDOCRINE TUMORS
(NET)

18:20
Presentation of Selected Abstracts

SESSION V
MOLECULAR SCREENING; IMAGING;
ARTIFICIAL INTELLIGENCE

18:50
Presentation of Selected Abstracts

19:00
DISCUSSANT/LECTURE: Early Detection
of Cancer in the Normal Population

19:24
DISCUSSANT/LECTURE: Artificial
Intelligence and Machine Learning in
Cancer Imaging

19:39
Presentation of Selected Abstracts

19:46
DISCUSSANT/LECTURE: Radiomics in
Imaging

20:01
Live Q&A With Key Opinion Leaders

20:21
Adjourn



Friday
3 July 2020

12:00
Welcome and Introduction;
Highlights of Day 2

12:15
Concurrent Symposia

SESSION VI
COLORECTAL CANCER I


13:15
Presentation of Selected Abstracts on
Colorectal Cancer

15:40
Live Q&A With Key Opinion Leaders

16:00
Break

16:10
Concurrent Symposia

17:10
KEYNOTE: Treatment Algorithms for MSI
and/or BRAF-Mutant Metastatic CRC



SESSION VII
COLORECTAL CANCER II

17:30
Presentation of Selected Abstracts on
Colorectal Cancer

20:10
Live Q&A With Key Opinion Leaders

20:30
Adjourn

Saturday
4 July 2020

12:00
Welcome and Introduction;
Highlights of Day 3

12:15
Concurrent Symposia

SESSION VIII
KEYNOTE PRESENTATIONS I

13:15
KEYNOTE: Women in Oncology

13:35
KEYNOTE: COVID-19 and Cancer

SESSION IX
RECTAL CANCER

13:55
Presentation of Selected Abstracts

14:24
KEYNOTE: Total Neoadjuvant Treatment
in Rectal Cancer: Reality or Myth?

14:44
Live Q&A With Key Opinion Leaders

SESSION X
KEYNOTE PRESENTATIONS II

15:04
KEYNOTE: Harmful Drug Interactions
in GI Oncology

15:24
KEYNOTE: Relevant Pathways in
Immuno-Oncology

15:44
Break

16:10
Concurrent Symposium

SESSION XI
POSTER DISCUSSIONS

17:10
HCC/Biliary Tract Cancer

17:20
Pancreatic Cancer

17:30
Colon Cancer

17:40
Other

17:50
Live Q&A With Key Opinion Leaders

18:10
Adjourn



NEW

In addition to our live scientific programme, a **13-session, 15.6-hour expanded on-demand programme** will be included in your registration. This programme will release therapy focused sessions over a period of several weeks following the virtual broadcast.



- CANCER OF THE PANCREAS AND BILIARY TRACT**
 - Hereditary Pancreatic Cancer: Genetics and Surveillance
 - Targeting the Microenvironment and the Immune System
 - How to Integrate and Interpret Best Imaging in Locally Advanced PDAC and What to Use for Response Evaluation: EUS, PET/CT, MRI
 - Debate: Neoadjuvant Treatment for Resectable Pancreatic Cancer
 - Treatment Modalities for Locally Advanced Pancreatic Cancer (Including SBRT, Ablation)
 - The Actual Algorithm in Advanced PDAC: A Strategic Approach (Covering Later Lines, PARP)
 - Druggable Molecular Alterations in Bile Duct Cancer
 - Locally Advanced Bile Duct Cancer

- PROGRESS IN GI CANCER**
 - How Can Consortia Contribute to the Progress in GI Oncology?
 - Contribution of the ARCAD Group
 - Contribution of the ACCENT Group
 - Teaching and Interpreting Statistics for Clinicians
 - Reporting on Endpoints: The Example in CRC

- ESOPHAGEAL AND GASTRIC CANCERS**
 - When and How to Treat Early Esophageal Cancer Endoscopically (Covering EMR, ESD, RFA)
 - Debate: GEJ Cancer: Locally Advanced Perioperative CT or Preoperative CRT
 - Adjuvant Treatment After Preoperative CRT in Esophageal or GEJ Cancer: When and How
 - Interaction Between Neoadjuvant Therapies, Comorbidity, and Surgery

- GASTRIC CANCER**
 - Treatment Algorithms in Metastatic Gastric Cancer
 - New HER2-Directed Agents in Gastric Cancer

- IMPACT OF PATIENT FACTORS IN DISEASE BIOLOGY IN GI CANCER: GENDER AND AGE**
 - The Explosion of CRC (or GI Cancer) in Young Adults: Why?
 - Why Does Gender Matter for Treatment?

- RELEVANT PATHWAYS IN GI CANCER: HOW RELEVANT AND HOW TO APPROACH THEM**
 - The HER2 Pathway in GI Cancer
 - FGFR and Other Fusions in GI Cancer
 - Should DPD Deficiency Be Tested Before Starting 5FU?
 - How to Interpret an NGS Sequencing Report
 - Debate: Tumor or Liquid Biopsies in the Future?

- KEYNOTE PRESENTATIONS**
 - KEYNOTE:** Integrating Health Economic Evaluation into Daily Practice in the COVID-19 Era
 - KEYNOTE:** New Promising PET Tracers

- HEPATOCELLULAR CANCER**
 - Can We Maximize the Benefit of IO in HCC?
 - Locoregional Treatment in HCC
 - Liver Transplantation in the COVID-19 Era

- MULTIMODALITY THERAPY FOR RECTAL CANCER**
 - Neoadjuvant Treatment: How and for Whom?
 - Organ Preserving Strategy
 - Local Excision (TEM/TAM) vs. Radical Resection: When and in Whom?
 - Case Presentations

- IMMUNE MECHANISMS AND IMMUNE THERAPY IN GI CANCER**
 - Biomarkers for Checkpoint Inhibitors in GI Cancer
 - How Can We Increase the Immunogenicity in MSS CRC?
 - The Link Between the Immune Microenvironment and Outcomes in Colorectal Cancer
 - New Immunotherapy Combinations (anti VEGF + CPI; CART; TKIs + CPI) in GI Cancers

- MOLECULAR BIOLOGY IN COLORECTAL CANCER**
 - Liver Transplantation in GI Cancer: A Reality or an Illusion? The Case in NET, Cholangiocarcinoma, and CRC
 - Genetic Risk Factors for GI Cancers/ Hereditary Syndromes

- COLORECTAL CANCER**
 - Treatment Algorithm in mCRC: How to Select First-Line Therapy
 - Treatment Algorithm in mCRC: Later Lines
 - Adjuvant Treatment for Stage II–III Colon Cancer

- NEW BREAKTHROUGH IN RARE CANCERS**
 - What is New in GIST in the Last 12 Months?
 - What is New in Pancreatic NETs in the Last 12 Months?
 - What is New in Non-Pancreatic NETs in the Last 12 Months?
 - What is New on Debulking and HIPEC in Peritoneal Carcinomatosis in the Last 12 Months?



Exhibition Experience

An innovative virtual Exhibition offers Congress participants a unique and interactive opportunity to engage with industry representatives to discover the latest approaches to treatment and groundbreaking medical technologies focused on treating patients with gastrointestinal cancers.

worldgicancer.com



Oncology
Learning Network

The ESMO World Congress on GI Cancer
is part of the Oncology Learning Network.

Visit Oncology Learning Network, the digital home of ESMO World Congress on GI Cancer, for exclusive access to session abstracts, multimedia interviews with key opinion leaders, and news coverage of this year's event and more at www.oncnnet.com

Continuing Education

ESMO-MORA

The Congress programme will be submitted for ESMO-MORA category 1 points accreditation. Re-certification is necessary for medical oncologists to remain professionally certified by ESMO. It also guarantees that a certified medical oncologist has continued to update her/his knowledge and possesses the necessary skills and standards for the practice of medical oncology.

Learning Objectives

After attending this Congress, participants should be able to:

- Identify current controversies in the management of patients with gastric or esophageal cancers
- Discuss contemporary treatment options for patients with gastric or esophageal cancers
- Comment on available treatment options for rare gastrointestinal and neuroendocrine tumors
- Describe the epidemiology and pathogenesis of hepatocellular carcinoma
- Discuss management of patients with liver cancer
- Identify adjuvant and neoadjuvant treatment options for patients with locally advanced and metastatic cancer of the pancreas
- Select the most appropriate detection, screening, and chemoprevention methods for colorectal cancer
- Describe the use of molecular markers for screening and prognosis of colorectal cancer and gastric cancer
- Select the most appropriate adjuvant and neoadjuvant treatments for colorectal cancer patients
- Comment on new agents in the treatment of colorectal cancer and the latest clinical trials results
- Identify treatment strategies for rectal cancer
- Distinguish appropriate surgical techniques for the treatment of gastrointestinal cancer

Who Should Attend

This Congress is specifically designed for practicing clinicians, gastroenterologists, hepatologists, pathologists, surgeons, medical oncologists, radiation oncologists, and clinical researchers who wish to review and update their knowledge and management of cancers of the gastrointestinal tract.

Registration

Groups

Groups of 10 or more should register by contacting the registration team directly at registration@imedex.com to complete the Group Registration Form.

ESMO Member	Registration Rates
Physician	€ 399
PhD, PharmD	€ 239
Nurse, Student, Trainee, Fellow, Resident, Nurse Practitioner, Physician Assistant	€ 59
Pharmaceutical Industry Representative	€ 649

Non-ESMO Member	Registration Rates
Physician	€ 499
PhD, PharmD	€ 299
Nurse, Student, Trainee, Fellow, Resident, Nurse Practitioner, Physician Assistant	€ 79
Pharmaceutical Industry Representative	€ 649

Register online at
worldgicancer.com

Call +1 678.242.0906
Email: registration@imedex.com

